|Otsuka Pharmaceutical, a Japanese drugmaker, has announced that they will collaborate with Click Therapeutics Inc. to bring “digital therapies for patients with major depression” / Photo by: 663highland via Wikimedia Commons|
The healthcare industry is currently positioned right now to reap the benefits of an increasingly technological wave of equipment within it. Otsuka Pharmaceutical, a Japanese drugmaker, has announced that they will collaborate with Click Therapeutics Inc. to bring “digital therapies for patients with major depression.”
It can be difficult to reach out to patients with major depression, but under this $300 million deal with Otsuka and Click Therapeutics, they are planning to bring therapeutics into the digital world, providing a “software-based intervention that has a direct impact on an illness or disease.
According to VentureBeat, Otsuka decided to partner with Click Therapeutics because they recognize that not all people have the money to seek medical attention whenever they can. By supplicating check-ups with this software, patients are at least given a rundown of their condition at the comfort of their own home.
The software, which will be called DTx--short for digital therapeutics--is also seen as a way for pharmaceutical companies access to data patients will ordinarily not be comfortable talking about, creating a collection of data that is updated in real time and are “accurate and normalized big data” that will “continue to provide powerful insights over time that can be used to improve treatment, or even create entirely new products.”
More access to data means hospitals and pharmaceutical companies will also be able to track side effects that most medications have, and use that data to improve drug creation and even calculate things like when to take the medicine or give out specific reminders about them.
This is actually a good venture, since the FDA also sees this as a step in the right direction, since the mix of software and medicine will also help “traditional companies extend their profits.”
Right now, digital therapeutics' main concerns are mental health and cognitive behavior conditions such as anxiety, depression, or substance abuse, also employing the use of cognitive behavioral therapy with them.